Low-dose alemtuzumab (Campath®) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics

@article{Khouri2004LowdoseA,
  title={Low-dose alemtuzumab (Campath®) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics},
  author={Issa F. Khouri and Maher Albitar and Rima Saliba and Cindy M Ippoliti and Yong Chao Ma and Michael J Keating and Richard E. Champlin},
  journal={Bone Marrow Transplantation},
  year={2004},
  volume={33},
  pages={833-837}
}
Summary:Alemtuzumab is effective in reducing the risk of acute graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (ASCT). Alemtuzumab may also delay immune reconstitution and reduce graft-versus-leukemia effects. The optimal dose has not been established. We investigated engraftment, acute GVHD incidence and severity, and pharmacokinetics of alemtuzumab associated with the use of low-dose alemtuzumab/cyclophosphamide/total body irradiation and ASCT for patients with… CONTINUE READING